6O3J

Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1 in complex with its MPER peptide epitope (region 671-683 of HIV-1 gp41) and phosphatidic acid (06:0 PA)

Summary for 6O3J

• Entry DOI: 10.2210/pdb6o3j/pdb
• Related: 6O3D 6O3G 6O3K 6O3L 6O3U 6O41 6O42
• Descriptor: PGZL1 light chain, PGZL1 heavy chain, MPER peptide, region 671-683 of HIV-1 gp41, ... (5 entities in total)
• Functional Keywords: pgzl1 anti hiv-1, gp41 mper, membrane lipids, broadly neutralising hiv-1 antibody, immune system
• Biological source: Homo sapiens; More
• Total number of polymer chains: 6
• Total formula weight: 99659.39

Authors

Irimia, A.,Wilson, I.A. (deposition date: 2019-02-26, release date: 2019-12-04, Last modification date: 2023-10-11)

Primary citation

Zhang, L.,Irimia, A.,He, L.,Landais, E.,Rantalainen, K.,Leaman, D.P.,Vollbrecht, T.,Stano, A.,Sands, D.I.,Kim, A.S.,Poignard, P.,Burton, D.R.,Murrell, B.,Ward, A.B.,Zhu, J.,Wilson, I.A.,Zwick, M.B.
An MPER antibody neutralizes HIV-1 using germline features shared among donors.
Nat Commun, 10:5389-5389, 2019

PubMed Abstract: The membrane-proximal external region (MPER) of HIV-1 envelope glycoprotein (Env) can be targeted by neutralizing antibodies of exceptional breadth. MPER antibodies usually have long, hydrophobic CDRH3s, lack activity as inferred germline precursors, are often from the minor IgG3 subclass, and some are polyreactive, such as 4E10. Here we describe an MPER broadly neutralizing antibody from the major IgG1 subclass, PGZL1, which shares germline V/D-region genes with 4E10, has a shorter CDRH3, and is less polyreactive. A recombinant sublineage variant pan-neutralizes a 130-isolate panel at 1.4 μg/ml (IC). Notably, a germline revertant with mature CDR3s neutralizes 12% of viruses and still binds MPER after DJ reversion. Crystal structures of lipid-bound PGZL1 variants and cryo-EM reconstruction of an Env-PGZL1 complex reveal how these antibodies recognize MPER and viral membrane. Discovery of common genetic and structural elements among MPER antibodies from different patients suggests that such antibodies could be elicited using carefully designed immunogens.

PubMed: 31772165
DOI: 10.1038/s41467-019-12973-1

Experimental method

X-RAY DIFFRACTION (3.416 Å)